Our latest news release for the trade media announces N4 Pharma’s research collaboration agreement with SRI, an independent non-for-profit research institute based in Silicon Valley, California, to combine Nuvec with SRI’s proprietary  FOX Three Molecular Guidance System™ (MGS)  to increase intercellular delivery to specific target cells.

On the back of this combined technology, both companies will work collaboratively to develop and pursue new business opportunities.

Find out more here.

We were pleased to share our latest updates with the pharmaceutical and biopharmaceutical trade press and some key publications in this field have published it: